Effects of Tocilizumab in COVID-19 patients: a cohort study
Abstract Background: Due to the lack of proven therapies, we evaluated the effects of early administration of tocilizumab for COVID-19. By inhibition of the IL-6 receptor, tocilizumab may help to mitigate the hyperinflammatory response associated with progressive respiratory failure caused by SARS-CoV-2. Methods: A retrospective, observational study was conducted on hospitalized adults who received intravenous tocilizumab for COVID-19 between March 23, 2020 and April 10, 2020. Results: Most patients were male (66.7%), Hispanic (63.3%) or Black (23.3%), with a median age of 54 years. Tocilizumab was administered at a median of 8 days (range 1-21) after initial symptoms and 2 days (range 0-12) after hospital admission. On the day of administration, the median PaO2/FiO2 was 166 (range 33-523) and 50 patients (83.3%) had ARDS. By day 30, 36 patients (60.0%) demonstrated clinical improvement, 9 (15.0%) died, 33 (55.0%) were discharged alive, and 18 (30.0%) remained hospitalized. Successful extubation occurred in 13 out of 29 patients (44.8%). Infectious complications occurred in 16 patients (26.7%) at a median of 10.5 days. There was an increase in PaO2/FiO2 and an initial reduction in CRP that was not sustained beyond day 10. Conclusions: Majority of patients demonstrated clinical improvement and were successfully discharged from the hospital alive after receiving tocilizumab. Similar to previous studies, infectious complications were not uncommon. We observed a rebound effect with CRP, which may suggest the need for higher or subsequent doses to adequately manage cytokine storm. Based on our findings, we believe that tocilizumab may have a role in the treatment of COVID-19, however randomized controlled studies are urgently needed..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
ResearchSquare.com - (2022) vom: 29. Juli Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vu, Christine [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-49532/v2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA034377336 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA034377336 | ||
| 003 | DE-627 | ||
| 005 | 20230429192946.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220113s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-49532/v2 |2 doi | |
| 035 | |a (DE-627)XRA034377336 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-49532/v2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vu, Christine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of Tocilizumab in COVID-19 patients: a cohort study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background: Due to the lack of proven therapies, we evaluated the effects of early administration of tocilizumab for COVID-19. By inhibition of the IL-6 receptor, tocilizumab may help to mitigate the hyperinflammatory response associated with progressive respiratory failure caused by SARS-CoV-2. Methods: A retrospective, observational study was conducted on hospitalized adults who received intravenous tocilizumab for COVID-19 between March 23, 2020 and April 10, 2020. Results: Most patients were male (66.7%), Hispanic (63.3%) or Black (23.3%), with a median age of 54 years. Tocilizumab was administered at a median of 8 days (range 1-21) after initial symptoms and 2 days (range 0-12) after hospital admission. On the day of administration, the median PaO2/FiO2 was 166 (range 33-523) and 50 patients (83.3%) had ARDS. By day 30, 36 patients (60.0%) demonstrated clinical improvement, 9 (15.0%) died, 33 (55.0%) were discharged alive, and 18 (30.0%) remained hospitalized. Successful extubation occurred in 13 out of 29 patients (44.8%). Infectious complications occurred in 16 patients (26.7%) at a median of 10.5 days. There was an increase in PaO2/FiO2 and an initial reduction in CRP that was not sustained beyond day 10. Conclusions: Majority of patients demonstrated clinical improvement and were successfully discharged from the hospital alive after receiving tocilizumab. Similar to previous studies, infectious complications were not uncommon. We observed a rebound effect with CRP, which may suggest the need for higher or subsequent doses to adequately manage cytokine storm. Based on our findings, we believe that tocilizumab may have a role in the treatment of COVID-19, however randomized controlled studies are urgently needed. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Deronde, Kailynn J |e verfasserin |4 aut | |
| 700 | 1 | |a Vega, Ana D |e verfasserin |4 aut | |
| 700 | 1 | |a Maxam, Meshell |e verfasserin |4 aut | |
| 700 | 1 | |a Holt, Gregory |e verfasserin |4 aut | |
| 700 | 1 | |a Natori, Yoichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Zamora, Jose Gonzales |e verfasserin |4 aut | |
| 700 | 1 | |a Salazar, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Boatwright, Renata |e verfasserin |4 aut | |
| 700 | 1 | |a Morris, Stephen R |e verfasserin |4 aut | |
| 700 | 1 | |a Corvino, Daniela de Lima |e verfasserin |4 aut | |
| 700 | 1 | |a Betances, Anmary Fernandez |e verfasserin |4 aut | |
| 700 | 1 | |a Colucci, Leah |e verfasserin |4 aut | |
| 700 | 1 | |a keegan, James |e verfasserin |4 aut | |
| 700 | 1 | |a Lopez, Andy |e verfasserin |4 aut | |
| 700 | 1 | |a Rezk, Andrew Hany |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez, Yvette |e verfasserin |4 aut | |
| 700 | 1 | |a Doblecki, Susanne |e verfasserin |4 aut | |
| 700 | 1 | |a Zerda, David De La |e verfasserin |4 aut | |
| 700 | 1 | |a Abbo, Lilian M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2022) vom: 29. Juli |
| 773 | 1 | 8 | |g year:2022 |g day:29 |g month:07 |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s12879-020-05701-4 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-49532/v2 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 29 |c 07 | ||